Adagrasib

Org: Sichuan Cancer Hospital and Institute, Chengdu, China, Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Lyon, France; Cancer Research Center of Lyon (INSERM 1052, CNRS 5286), Lyon, France; Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France, Institut de Cancérologie de l'Ouest, Saint-Herblain, France, Hospital Universitario Son Espases, Mallorca, Spain, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy,

Abstract

Therapeutic implications of acquired high tumor mutational burden (TMB-H) after targeted therapy (TT) in metastatic colorectal cancer (mCRC).

Org: Memorial Sloan Kettering Cancer Center,

Abstract

FIT-001: A phase 1 clinical trial of the farnesyl transferase inhibitor KO-2806 alone or as part of combination therapy for advanced solid tumors.

Org: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Carbone Cancer Center, University of Wisconsin, Madison, WI, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL,

Abstract

Impact of trial eligibility criteria on enrollment to KRASG12C inhibitor trials in patients with non-small cell lung cancer.

Org: NYP/Columbia,

Clinical trial

A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

Status: Withdrawn, Estimated PCD: 2024-01-16

Clinical trial

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Status: Not yet recruiting, Estimated PCD: 2026-03-01

Clinical trial

A Multicentre, Single-arm Phase II Trial of Adagrasib in Patients With KRASG12C-mutant NSCLC, Including the Elderly (≥70 Years) or Patients With Poor Performance Status

Status: Recruiting, Estimated PCD: 2025-10-01

Clinical trial

Phase 2 Trial of Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab in Resectable Non-Small Cell Lung Cancer (Neo-KAN)

Status: Recruiting, Estimated PCD: 2025-11-01

Clinical trial

Genomically-Guided Treatment Trial in Brain Metastases

Status: Recruiting, Estimated PCD: 2024-10-01

Clinical trial

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Status: Recruiting, Estimated PCD: 2028-08-25

Clinical trial

Phase II Study of Adagrasib + Stereotactic Radiosurgery (SRS) for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

Status: Recruiting, Estimated PCD: 2026-03-01

Clinical trial

A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Status: Recruiting, Estimated PCD: 2028-10-31

Abstract

The impact of PD-L1 expression and co-mutations on outcome of KRAS-driven non-small-cell lung cancer.

Org: Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, Thoraxklinik, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), University Hospital Heidelberg,

Abstract

Phase I study of NEROFE and doxorubicin in KRAS-mutated ST2-positive solid tumors.

Org: Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Georgetown Lombardi Comprehensive Cancer Center, Georgetown - Lombardi Comprehensive Cancer Center,

Abstract

SPARK, studying pathways of resistance in KRAS-driven cancers: A remote plasma ctDNA participation study to identify mechanisms of resistance to KRAS inhibitors.

Org: Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology, Kras Kickers, GO2 Foundation for Lung Cancer, Addario Lung Cancer Medical Institute,

Abstract

Impact of novel pan-RAS inhibitors on efficacy and resistance to AMG-510 and MRTX-1133 in pancreatic cancer cell lines.

Org: Qualigen Therapeutics, Dept. Medicine, Brown Cancer Center University of Louisville, Departments of Medicine and Pharmacology & Toxicology, James Graham Brown Cancer Center,

Abstract

A phase 1a/1b study of aurora kinase A inhibitor VIC-1911 as monotherapy and in combination with sotorasib for the treatment of KRAS G12C-mutant non–small-cell lung cancer.

Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale School of Medicine, New Haven, CT, NYU Langone-Laura and Isaac Perlmutter Cancer Center, New York, NY,

Abstract

ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).

Org: Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, Cedars-Sinai Medical Center, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Harold C. Simmons Comprehensive Cancer Center,

Clinical trial

A Phase II, Multicentric, Open Label, Non-randomized, Interventional Study of Pembrolizumab in Combination With Electrochemotherapy in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

Status: Withdrawn, Estimated PCD: 2023-12-01

Product

Pembrolizumab

Product

Pembrolizumab + Quavonlimab + Lenvatinib

Product

IMC-F106C + Pembrolizumab

Product

Platinum-based chemotherapy + pembrolizumab

Product